An improved anti-addiction medication

"Design and Mechanism of (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent γ-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Addiction"
Journal of the American Chemical Society

Drug addiction continues to plague vast numbers of people across the world, destroying and ending lives, while attempts to develop more effective pharmaceutical addiction treatments continue. Scientists now report in the Journal of the American Chemical Society the development of a potent new medicine to fight addiction, which might also be an effective treatment for epilepsy and other conditions.

Vigabatrin is an anti-epilepsy medication approved by the Food and Drug Administration that has also been shown to be effective against addiction to cocaine, nicotine, methamphetamine, heroin and alcohol in animal models. In humans, vigabatrin eliminates cocaine addiction in 28 percent of patients. It works by blocking an enzyme, γ-aminobutyric acid (GABA) aminotransferase, which breaks down GABA. The result is higher levels of this neurotransmitter in the brain and diminished narcotic-activated release of dopamine. Long-term vigabatrin therapy can have serious side effects however, causing eye damage in up to 40 percent of those treated. So, Richard B. Silverman, Stephen L. Dewey and colleagues wanted to develop a more potent inhibitor of GABA aminotransferase with fewer side effects.

In previous work, the researchers designed a compound, CPP-115, that is 186 times more efficient in inactivating GABA aminotransferase than vigabatrin. In this study, they used computational molecular dynamics simulations of CPP-115 in complex with the enzyme to develop a new and improved agent with 10 times greater efficiency. The drug should also be less likely to cause side effects, as it has fewer off-target activities in in vitro tests. In initial rat experiments, the new compound was far better at blocking dopamine release after a cocaine or nicotine stimulus than CPP-115. The researchers say that future work could examine whether the computational approach could be generalized to improve other mechanism-based enzyme inhibitors in the laboratory before testing them on animals.

The authors acknowledge funding from the National Institutes of Health.

Note: ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies.